NEW YORK (GenomeWeb News) - Lexicon Genetics today said it has entered into agreements with unspecified investors to purchase up to 10,582,011 shares of its stock.
The Woodlands, Texas-based biopharmaceutical company said "select institutional investors" agreed to purchase the stock at a price of $3.78 per share, and that it expects net proceeds of up to $37.5 million.
The agents for the placement were Banc of America Securities and Lazard Capital Markets.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.